Ascelia Pharma AB ACE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 10.58
- Day Range
- SEK 10.34–17.98
- 52-Week Range
- SEK 2.62–17.98
- Bid/Ask
- SEK 12.26 / SEK 12.40
- Market Cap
- SEK 416.57 Mil
- Volume/Avg
- 3.6 Mil / 243,582
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo, Sweden, focused on the development of novel drugs to improve the life expectancy and quality of life for people living with cancer. The company is focused on two clinical-stage product candidates under development: Mangoral and Oncoral.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.ascelia.com
Comparables
Valuation
|
Metric
|
ACE
|
MCAP
|
GENO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 40.92 | 29.11 |
Price/Book Value | 4.81 | 6.30 | 9.56 |
Price/Sales | — | 4.08 | 11.52 |
Price/Cash Flow | — | 21.76 | 28.32 |
Price/Earnings
ACE
MCAP
GENO
Financial Strength
|
Metric
|
ACE
|
MCAP
|
GENO
|
|---|---|---|---|
Quick Ratio | 1.98 | 1.35 | 6.79 |
Current Ratio | 2.30 | 2.23 | 7.49 |
Interest Coverage | — | 14.80 | 23.95 |
Quick Ratio
ACE
MCAP
GENO
Profitability
|
Metric
|
ACE
|
MCAP
|
GENO
|
|---|---|---|---|
Return on Assets (Normalized) | −81.49% | 10.75% | 26.91% |
Return on Equity (Normalized) | −98.14% | 17.72% | 35.49% |
Return on Invested Capital (Normalized) | −88.49% | 13.91% | 31.99% |
Return on Assets
ACE
MCAP
GENO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bnnlmnwzz | Nvc | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lphjnqp | Xbvfx | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wctkttns | Gwrtht | $99.2 Bil | |
MRNA
| Moderna Inc | Mxcfydsg | Spkk | $42.7 Bil | |
ARGX
| argenx SE ADR | Kpjfsck | Xxwy | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Rvlcrwkd | Slqk | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kdsbfsb | Pzbdtq | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lygdyfpm | Mmtcfv | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lzmjsthpxs | Blnsl | $12.7 Bil | |
INCY
| Incyte Corp | Hhzfnmzq | Ybkgfws | $11.9 Bil |